Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has 2 licensing announcements in this dataset, dated 2026-05-12 to 2026-09-29.
- Country / operating region
- China
- Ticker
- 查無
- Headquarters
- 查無
- Founded
- 1970
- Business
- Pharmaceutical research, development, manufacturing and commercialization
- Website
- www.hengrui.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| Four Hengrui-originated assets; five joint-discovery programs | 查無 | 查無 | 查無 | 2026-05-12 |
| HRS-1596 | GLP-1R; GIPR | 查無 | Phase I-ready | 2026-09-29 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| SHR-A1811 | PHASE3 | NCT06057610 | ACTIVE_NOT_RECRUITING | Jiangsu HengRui Medicine Co., Ltd. | 2026-09-09 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-05-12 | Bristol Myers Squibb | Four Hengrui-originated assets; five joint-discovery programs | USD 600m | USD 175m First anniversary | 查無 | ≤ USD 15200m | Contingent anniversary (2028) USD 175m |
| 2026-09-29 | Novo Nordisk A/S | HRS-1596 | USD 300m | 查無 | 查無 | ≤ USD 2600m | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| Bristol Myers Squibb | Worldwide excluding mainland China, Hong Kong and Macau | Tiered royalties on net sales outside the Hengrui Territory. |
| Novo Nordisk A/S | Worldwide excluding mainland China, Hong Kong, Macau and Taiwan | Royalties on net sales in licensed territory. |
Asia ADC assets and licensing deals
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無